Supreme Court Copaxone Case May Weaken Federal Circuit Review Of Patent Claims
This article was originally published in The Pink Sheet Daily
Teva has a chance to block generic competition until Sept. 1, 2015; high court declines to hear False Claims Act case against Takeda and a challenge to Allergan’s Combigan patent.
You may also be interested in...
Teva Appeals In Delhi High Court To Block Natco’s Export Of Glatiramer
Teva’s petition to stop Natco from exporting glatiramer was dismissed by the Delhi High in February. The company has now appealed to a double bench in its continued efforts to prove that Natco’s move to export the compound infringes its international patents.
Takeda False Claim Act Case May Allow Supreme Court To Set Evidence Threshold
High court seeks Solicitor General’s views on whether a whistleblower must identify a specific false claim submitted to the government or just have evidence to infer the submission; Solicitor General has previously supported latter position.
Teva’s Final Copaxone Firewall Is Complexity Of ANDA Review After Court Tosses Patent
Federal Circuit finds claims covering Copaxone’s latest expiring patent are invalid; Mylan says it plans to launch its generic of the MS drug in May 2014.